Sushen Pharma Care Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-01-2025
- Paid Up Capital ₹ 0.10 M
as on 11-01-2025
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit -302.17%
(FY 2022)
- Ebitda -302.17%
(FY 2022)
- Net Worth -42.41%
(FY 2022)
- Total Assets 5.31%
(FY 2022)
About Sushen Pharma Care
The Corporate was formerly known as Sushen Ayu Research & Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Niraj Vaghela, Chunilal Vaghela, Alpa Vaghela, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC063998
- Company No.
063998
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Feb 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sushen Pharma Care?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niraj Vaghela  | Director | 01-Jul-2019 | Current |
| Chunilal Vaghela | Director | 10-Feb-2011 | Current |
| Alpa Vaghela | Director | 10-Oct-2019 | Current |
| Sonal Vaghela | Director | 10-Oct-2019 | Current |
| Riddhi Vaghela | Director | 10-Oct-2019 | Current |
Financial Performance of Sushen Pharma Care.
Sushen Pharma Care Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 302.17% decrease in profit. The company's net worth observed a substantial decline by a decrease of 42.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sushen Pharma Care?
In 2021, Sushen Pharma Care had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rooshi Petro-Chem Private LimitedActive 15 years 10 monthsNiraj Vaghela and Chunilal Vaghela are mutual person
- Rashmi Smruti Seva FoundationActive 5 years 4 months
Niraj Vaghela and Chunilal Vaghela are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sushen Pharma Care?
Unlock and access historical data on people associated with Sushen Pharma Care, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sushen Pharma Care, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sushen Pharma Care's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
